Coronary Artery Disease, Percutaneous Transluminal Coronary Angioplasty
Conditions
Keywords
XIENCE Xpedition, Routine Clinical Practice, Alpine, Sierra
Brief summary
The purpose of this study is to evaluate effectiveness and safety of XIENCE Xpedition/Alpine/Sierra in Routine Clinical Practice
Interventions
DEVICEXIENCE Xpedition/Alpine/Sierra
Sponsors
CardioVascular Research Foundation, Korea
Abbott
Seung-Jung Park
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 19 and more * Intervention with XIENCE Xpedition or Alpine or Sierra everolimus eluting coronary stent * Agreed with written informed consent form
Exclusion criteria
* Intervention with XIENCE Xpedition or Alpine or Sierra everolimus eluting coronary stent and other drug eluting stent at the same time * Life expectancy of 1year and under * Cardiac shock
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Composite event rate | 1year | Death, non fatal myocardial infarction, Target Vessel Revascularization |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cardiac death | 5year | — |
| Myocardial infarction | 5year | — |
| Composite event of death or myocardial infarction | 5year | — |
| Composite event of cardiac death or myocardial infarction | 5year | — |
| All death | 5year | — |
| Target lesion revascularization | 5year | — |
| Stent thrombosis by an Academic Research Consortium (ARC) criteria | 5year | — |
| Stroke | 5year | — |
| procedural success | 3day | defined as less than 30% residual stenosis at the completion of procedure without death or Q wave myocardial infarction or urgent revascularization participants will be followed for the duration of hospital stay, an expected average of 3days. |
| Target Vessel revascularization | 5year | — |
Countries
South Korea
Outcome results
None listed